NVO Stock Plummets as Novo Nordisk Heart Drug Fails Late-Stage Trial

Novo Nordisk stock experienced a significant decline, plummeting by 9% following the failure of a late-stage trial for its heart drug. The market reaction was immediate as NVO shares sank after the clinical results were announced. This failure in the advanced testing phase for the cardiovascular medication led to a sharp drop in the company's valuation, reflecting investor disappointment in the drug's inability to meet the necessary trial endpoints for regulatory approval.